DK0723440T3 - Therapeutic delivery compositions and methods for using the same - Google Patents

Therapeutic delivery compositions and methods for using the same

Info

Publication number
DK0723440T3
DK0723440T3 DK94931827T DK94931827T DK0723440T3 DK 0723440 T3 DK0723440 T3 DK 0723440T3 DK 94931827 T DK94931827 T DK 94931827T DK 94931827 T DK94931827 T DK 94931827T DK 0723440 T3 DK0723440 T3 DK 0723440T3
Authority
DK
Denmark
Prior art keywords
approximately
c2h4o
methods
c3h6o
integer
Prior art date
Application number
DK94931827T
Other languages
Danish (da)
Inventor
Konstantin G Kousoulas
Original Assignee
Cytrx Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytrx Corp filed Critical Cytrx Corp
Application granted granted Critical
Publication of DK0723440T3 publication Critical patent/DK0723440T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

The present invention relates to compositions and methods for treating infectious diseases and genetic disorders through gene therapy and intracellular delivery of antisense oligonucleotides or other nucleic acid sequences. The present invention comprises a therapeutic delivery composition effective for treating a disease state comprising an administerable admixture of an effective amount of a therapeutic compound capable of altering nucleic acid sequence function and an effective amount of a surface active nonionic block copolymer having the following general formula: HO(C2H4O)b(C3H6O)a(C2H4O)bH wherein a is an integer such that the hydrophobe represented by (C3H6O) has a molecular weight of approximately 750 and approximately 15,000, preferably between approximately 2,250 and approximately 15,000, more preferably between approximately 3,250 and approximately 15,000, and b is an integer such that the hydrophile portion represented by (C2H4O) constitutes approximately 1 % to approximately 50 % by weight of the compound, preferably approximately 5 % to approximately 20 %.
DK94931827T 1993-10-15 1994-10-12 Therapeutic delivery compositions and methods for using the same DK0723440T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13827193A 1993-10-15 1993-10-15
PCT/US1994/011594 WO1995010265A1 (en) 1993-10-15 1994-10-12 Therapeutic delivery compositions and methods of use thereof

Publications (1)

Publication Number Publication Date
DK0723440T3 true DK0723440T3 (en) 2003-02-24

Family

ID=22481270

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94931827T DK0723440T3 (en) 1993-10-15 1994-10-12 Therapeutic delivery compositions and methods for using the same

Country Status (9)

Country Link
EP (1) EP0723440B1 (en)
JP (1) JP3819422B2 (en)
KR (1) KR100218140B1 (en)
AT (1) ATE230260T1 (en)
AU (1) AU8076494A (en)
DE (1) DE69431959T2 (en)
DK (1) DK0723440T3 (en)
ES (1) ES2189808T3 (en)
WO (1) WO1995010265A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1181937A3 (en) 1994-08-09 2004-02-04 Cytrx Corporation Novel vaccine adjuvant and vaccine
US5656611A (en) * 1994-11-18 1997-08-12 Supratek Pharma Inc. Polynucleotide compositions
US6040295A (en) 1995-01-13 2000-03-21 Genemedicine, Inc. Formulated nucleic acid compositions and methods of administering the same for gene therapy
US7002027B1 (en) 1996-01-08 2006-02-21 Canji, Inc. Compositions and methods for therapeutic use
US5789244A (en) * 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
US6392069B2 (en) 1996-01-08 2002-05-21 Canji, Inc. Compositions for enhancing delivery of nucleic acids to cells
US6673914B1 (en) 1998-01-22 2004-01-06 John Wayne Cancer Institute Human tumor-associated gene
KR100360827B1 (en) * 1999-08-14 2002-11-18 주식회사 삼양사 Polymeric composition for solubilizing poorly water soluble drugs and process for the preparation thereof
EP1278551A2 (en) 2000-04-21 2003-01-29 Vical Incorporated Compositions and methods for (in vivo) delivery of polynucleotide-based therapeutics
EP1232758A1 (en) * 2001-02-19 2002-08-21 Aventis Pasteur Polynucleotide formulated for improved intracellular transfer
WO2003053365A2 (en) 2001-12-20 2003-07-03 Schering-Plough Corporation Syn3 compositions and methods
NZ543970A (en) 2003-06-04 2008-09-26 Canji Inc Methods and compositions for interferon therapy
EP3311824B1 (en) 2013-02-05 2020-03-25 The Board of Trustees of the Leland Stanford Junior University Cd47 targeted therapies for the treatment of infectious disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3308458A1 (en) * 1983-03-10 1984-09-13 Behringwerke Ag, 3550 Marburg METHOD FOR ADJUVING VACCINES
IT1191608B (en) * 1985-02-01 1988-03-23 Zambon Spa PHARMACEUTICAL COMPOSITION AND PHARMACEUTICAL FORMS THAT CONTAIN IT
AU6334586A (en) * 1986-05-15 1987-12-01 Emory University Composition and method for treating a thrombus and embolus
US5037644A (en) * 1986-10-27 1991-08-06 Cetus Corporation Pharmaceutical compositions of recombinant interleukin-2 and formulation processes
US5221495A (en) * 1990-04-13 1993-06-22 Colgate-Palmolive Company Enzyme stabilizing composition and stabilized enzyme containing built detergent compositions
CA2106474C (en) * 1991-03-19 2004-02-10 R. Martin Emanuele Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
AU3129993A (en) * 1991-11-08 1993-06-07 Massachusetts Institute Of Technology Localized oligonucleotide therapy

Also Published As

Publication number Publication date
ES2189808T3 (en) 2003-07-16
AU8076494A (en) 1995-05-04
WO1995010265A1 (en) 1995-04-20
KR960704534A (en) 1996-10-09
KR100218140B1 (en) 1999-09-01
DE69431959D1 (en) 2003-02-06
EP0723440A4 (en) 1997-06-11
ATE230260T1 (en) 2003-01-15
JP3819422B2 (en) 2006-09-06
EP0723440B1 (en) 2003-01-02
JPH09503788A (en) 1997-04-15
DE69431959T2 (en) 2003-11-06
EP0723440A1 (en) 1996-07-31

Similar Documents

Publication Publication Date Title
DK0723440T3 (en) Therapeutic delivery compositions and methods for using the same
RU2175337C2 (en) Polynucleotide compositions
EP0677056B1 (en) Oligonucleotide alkylphosphonates and alkylphosphonothioates
AU696635B2 (en) Stabilized oligonucleotides and their use
KR950702626A (en) Self-stabilized oligonucleotides as therapeutic agents (SELF-STABILIZED LOIGONUCLEOTIDES AS THERAPEUTIC AGENTS)
BR9106729A (en) COMPOUND, PROCESSES TO INHIBIT NUCLEASE DEGRADATION OF COMPOUNDS AND TO STABILIZE SEQUENCES OF NICLEOTIDEOS OR OLIGONUCLEOSIDEOS, COMPOSITION USABLE TO INHIBIT GENE EXPRESSION AND PROCESS TO INHIBIT EXPRESSION OF GENES IN A NEEDING MAMMALIAN NEEDING NEEDS
HUE027064T2 (en) Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity
MX9406552A (en) Method, compositions and devices for administration of naked nucleotides which express biologically active peptides.
JP2004536103A5 (en)
ES2165969T3 (en) AROMATIC CONDENSED NITROGEN COMPOUNDS 5.5 ARIL-SUBSTITUTED AS ANTI-INFLAMMATORY AGENTS.
WO2002032912A3 (en) Phosphinoamidite carboxylates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge
HK1048990A1 (en) Novel compounds.
WO2001002424A3 (en) Peptide boronic acid inhibitors of hepatitis c virus protease
ITPD920071A1 (en) USE OF HYALURONIC ACID PREPARATIONS FOR THE FORMATION OF BONE TISSUE
GEP20022824B (en) Antipicornaviral Compounds, Pharmaceutical Compositions Containing the Same and Methods for Treatment
HK1080764A1 (en) Implant for transport and release for pharmacologically active agents as well as a process for producing the same
CA2457034A1 (en) Ophthalmic composition comprising an ascomycin
WO2002062767A1 (en) Novel quinazoline derivatives
HUP0002683A2 (en) Compositions and methods for enhancing delivery of therapeutic agents to cells
FR2790757B1 (en) OLIGONUCLEOTIDES CONTAINING AN ANTI-SENSE SEQUENCE STABILIZED BY A SECONDARY STRUCTURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME.
CA2377290A1 (en) Utilization of a highly fluorinated oligomeric alkane in ophthalmology
RS50046B (en) PHARMACEUTICAL COMPOSITIONS OF TIZOXANIDE AND NITAZOXANIDE
CA2174122A1 (en) Therapeutic delivery compositions and methods of use thereof
AU3881095A (en) Double-stranded oligonucleotide and carcinostatic agent containing the same as active ingredient
EP0739901A3 (en) Novel oligoribonucleotide derivatives and application thereof to antiviral agents